Skyhawk Therapeutics, Inc.

Skyhawk Therapeutics is a clinical-stage biotechnology company that discovers and develops small-molecule therapeutics designed to modify RNA expression. Its pipeline comprises RNA-modifying drug candidates for diseases including neurodegenerative and neuromuscular disorders, oncology, fibrosis, and other conditions. The company’s mission is to improve disease treatment for patients worldwide by developing medicines that target RNA, with the goal of addressing challenging diseases.